Novo Nordisk Tops Global List of 100 Most Sustainable Companies

(3BL Media / theCSRfeed) January 25, 2012 - Today at the World Economic Forum in Davos, Switzerland, Novo Nordisk was ranked number one in the Global 100 Most Sustainable Corporations in the World index. The index is published annually since 2005 by Corporate Knights – a Canadian and North American business magazine.   Lise Kingo, executive vice president of Novo Nordisk, is proud of the acknowledgment and emphasises Novo Nordisk’s commitment to continue the sustainable growth path that the company has pursued for more than two decades.   “This is a wonderful recognition of our Triple Bottom Line approach and a clear indication that Novo Nordisk is poised for long-term business success. But most importantly it is an encouragement to continue to find new ways of growing our business in a way that is profitable, responsible and valuable for patients, employees and society”, Lise Kingo says.   The aim of the Global 100 is to highlight the global companies, which are most proactive in managing environmental, social and corporate governance issues. Out of the 11 key performance indicators, Novo Nordisk is rated among the best in energy productivity, greenhouse gas productivity, CEO to Average Employee Pay ratio, employee turnover and linking the remuneration of senior executives with the achievement of sustainability targets.     Corporate Knights selects the Global 100 from a base of 4,000 developed and emerging market stocks, based on their sustainability ratings from the world’s largest sustainability research consortium, The Global Sustainability Research Alliance which integrates research from 10 leading firms across the globe including Goldman Sachs | GS SUSTAIN, Société Générale, EIRIS, and RiskMetrics Group.   Number two and three on the list are Natura Cosmeticos SA and Statoil, respectively. Novo Nordisk’s sister company, Novozymes is rated number four.   For more information about Global 100: www.global100.org   About Novo Nordisk Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,500 employees in 74 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).   Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance. Novo Nordisk is listed in the 2010/2011 Dow Jones Sustainability Indices with a gold class rating. For more information, visit novonordisk.com/sustainability.   To read more about Novo Nordisk’s sustainability efforts, go to: www.novonordisk.com/sustainability   Further information:   Charlotte Zarp-Andersson Media Relations Manager Tel +45 3079 7603 email: czpa@novonordisk.com 

NOVO20478